Efficacy and safety of Tislelizumab combined with Axitinib as first-line treatment for intermediate- and high-risk metastatic clear-cell renal cell carcinoma
ObjectiveTo evaluate the efficacy and safety of Tislelizumab combined with Axitinib in the treatment of intermediate-high risk metastatic clear-cell renal cell carcinoma (ccRCC).MethodsFrom September 2021 to June 2023, a total of 20 untreated patients with intermediate-high risk metastatic advanced...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-05-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2025.1618898/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|